Modulation of the metabolism of β-L-(-)-2',3'-dideoxy-3'-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 918-923

  Rahn, Jennifer J ^a,b   Kieller, Dawn M ^a   Tyrrell, D Lorne J ^a   Gati, Wendy P ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Biomira Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANTIVIRUS AGENT; CARRIER PROTEIN; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DRUG METABOLITE; FLUDARABINE; LAMIVUDINE; NITROBENZYLTHIOINOSINE; NUCLEOSIDE; THYMIDINE;

ANIMAL CELL; ARTICLE; CYTOTOXICITY; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DUCK; HUMAN; HUMAN CELL; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL;

EID: 0030984310     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.918     Document Type: Article

References (38)

1. Adjei, A. A., L. Dagnino, M. M. Y. Wong, and A. R. P. Paterson. 1992. Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine. Cancer Chemother. Pharmacol. 31:71-75.
2. Alessi-Severini, S., W. P. Gati, A. R. Belch, and A. R. P. Paterson. 1995. Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. Leukemia 9:1674-1679.
3. Alley, M. C., D. A. Scudiero, A. Monks, M. L. Hursey, M. J. Czerwinski, D. L. Fine, B. J. Abbott, J. G. Mayo, R. H. Shoemaker, and M. R. Boyd. 1988. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:589-601.
4. Balzarini, J., D. A. Cooney, M. Dalal, G.-J. Kang, J. E. Cupp, E. De Clercq, S. Broder, and D. G. Johns. 1987. 2′,3′-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol. Pharmacol. 32: 798-806.
5. Belt, J. A., N. M. Marina, D. A. Phelps, and C. R. Crawford. 1993. Nucleo-side transport in normal and neoplastic cells. Adv. Enzyme Regul. 33:235-252.
6. Blumenreich, M. S., T.-C. Chou, M. Andreeff, K. Vale, B. D. Clarkson, and C. W. Young. 1984. Thymidine as a kinetic and biochemical modulator of 1-β-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia. Cancer Res. 44:825-830.
7. Cammack, N., P. Rouse, C. L. P. Marr, P. J. Reid, R. E. Boehme, J. A. V. Coates, C. R. Penn, and J. M. Cameron. 1992. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem. Pharmacol. 43:2059-2064.
8. Cass, C. E. 1995. Nucleoside transport, p. 403-451. In N. H. Georgopapadakou (ed.). Drug transport in antimicrobial therapy and anticancer therapy. Marcel Dekker, Inc., New York, N.Y.
9. Chang, C.-N., V. Skalski, J. H. Zhou, and Y.-C. Cheng. 1992. Biochemical pharmacology of (+) and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J. Biol. Chem. 267:22414-22420.
10. Coates, J. A. V., N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. 1992. (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type-1 and type-2 replication in vitro. Antimicrob. Agents Chemother. 36:733-739.
11. Coates, J. A. V., N. Cammack, H. J. Jenkinson, I. M. Mutton, B. A. Pearson, R. Storer, J. M. Cameron, and C. R. Penn. 1992. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH-189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob. Agents Chemother. 36:202-205.
12. Doong, S.-L., C.-H. Tsai, R. F. Schinazi, D. C. Liotta, and Y.-C. Cheng. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogs. Proc. Natl. Acad. Sci. USA 88:8495-8499.
13. Dulbecco, R., and M. Vogt. 1954. Plaque formation and isolation of pure lines with poliomyelitis viruses. J. Exp. Med. 99:167-182.
14. El Kouni, M. H., N. J. Messier, and S. Cha. 1987. Treatment of schistosomiasis by purine nucleoside analogs in combination with nucleoside transport inhibitors. Biochem. Pharmacol. 36:3815-3821.
15. Gandhi, V., E. Estey, M. J. Keating, and W. Plunkett. 1993. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol. 11:116-124.
16. Gandhi, V., and W. Plunkett. 1988. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 48:329-334.
17. Gati, W. P., D. L. J. Tyrrell, and D. M. Kieller. Unpublished data.
18. Greenberg, M. L., H. S. Allaudeen, and M. S. Hershfield. 1990. Metabolism, toxicity, and anti-HIV activity of 2′-deoxy-3′-thiacytidine (BCH-189) in T and B cell lines. Ann. N. Y. Acad. Sci. 616:517-518.
19. Hart, G. J., D. C. Orr, C. R. Penn, H. T. Figueiredo, N. M. Gray, R. E. Boehme, and J. M. Cameron. 1992. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob. Agents Chemother. 36:1688-1694.
20. Heinemann, V., L. W. Hertel, G. B. Grindey, and W. Plunkett. 1988. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 48:4024-4031.
21. Heinemann, V., Y.-Z. Xu, S. Chubb, A. Sen, L. W. Hertel, G. B. Grindey, and W. Plunkett. 1992. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res. 52:533-539.
22. Jarvis, S. M., and J. D. Young. 1987. Photoaffinity labelling of nucleoside transporter polypeptides. Pharmacol. Ther. 32:339-359.
23. Kemena, A., M. Fernandez, J. Bauman, M. Keating, and W. Plunkett. 1991. A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids. Clin. Chim. Acta 200:95-106.
24. Lynch, T. P., E. S. Jakobs, J. H. Paran, and A. R. P. Paterson. 1981. Treatment of mouse neoplasms with high doses of tubercidin. Cancer Res. 41:3200-3204.
25. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63.
26. Motulsky, H. J., and L. A. Ransnas. 1987. Fitting curves to data using nonlinear regression; a practical and nonmathematical review. FASEB J. 1:365-374.
27. Paff, M. T., D. R. Averett, K. L. Prus, W. H. Miller, and D. J. Nelson. 1994. Intracellular metabolism of (-)- and (+)-ris-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells. Antimicrob. Agents Chemother. 38:1230-1238.
28. Paterson, A. R. P., A. S. Clanachan, J. D. Craik, W. P. Gati, E. S. Jakobs, J. S. Wiley, and C. E. Cass. 1991. Plasma membrane transport of nudeosides, nucleobases and nucleotides: an overview, p. 133-149. In S. Imai and M. Nakazawa (ed.), Role of adenosine and adenine nucleotides in the biological system. Elsevier, Tokyo, Japan.
29. Paterson, A. R. P., E. R. Harley, and C. E. Cass. 1984. Inward fluxes of adenosine in erythrocytes and cultured cells measured by a quenched-flow method. Biochem. J. 224:1001-1008.
30. Paterson, A. R. P., E. S. Jakobs, E. R. Harley, C. E. Cass, and M. J. Robins. 1983. Inhibitors of nucleoside transport as probes and drugs, p. 41-56. In Y.-C. Cheng. B. Goz, and M. Minkoff (ed.), Development of target-oriented anticancer drugs. Raven Press, New York, N.Y.
31. Pluda, J. M., T. P. Cooley, J. S. G. Montaner, L. E. Shay, N. E. Reinhalter, S. N. Warthan, J. Ruedy, H. M. Hirst, C. A. Vicary, J. B. Quinn, G. J. Yuen, M. A. Wainberg, M. Rubin, and R. Yarchoan. 1995. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 171:1438-1447.
32. Schinazi, R. F., C. K. Chu, A. Peck. A. McMillan, R. Mathis, D. Cannon, L. S. Jeong, J. W. Beach, W. B. Choi, S. Yeola, and D. C. Liotta. 1992. Activities of the four optical isoniers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob. Agents Chemother. 36:672-676.
33. Severini, A., X.-Y. Liu, J. S. Wilson, and D. L. J. Tyrrell. 1995. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 39:1430-1435.
34. Shewach, D. S., D. C. Liotta, and R. F. Schinazi. 1993. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase. Biochem. Pharmacol. 45:1540-1543.
35. Sirotnak, F. M., P. L. Chello, D. M. Dorick, and J. A. Montgomery. 1983. Specificity of systems mediating transport of adenosine, 9-β-D-arabinofuranosyl-2-fluoroadenine, and other purine nucleoside analogs in L1210 cells. Cancer Res. 43:104-109.
36. Sommadossi, J. P., R. F. Schinazi, C. K. Chu, and M. Y. Xie. 1992. Comparison of cytotoxicity of the (-)- and (+ )-enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrow progenitor cells. Biochem. Pharmacol. 44:1921-1925.
37. Starnes, M. C., and Y.-C. Cheng. 1987. Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem. 262:988-991.
38. van Leeuwen, R., C. Katlama, V. Kitchen, C. A. B. Boucher. R. Tubiana, M. McBride, D. Ingrand, J. Weber, A. Hill, H. McDade, and S. A. Danner. 1995. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis. 171:1166-1171.